Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, Inc. (NASDAQ:ORKA), disposed of 10,000 shares of the company's common stock on November 12, 2026, generating proceeds of approximately $1.05 million. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that Agarwal established on February 11, 2026.
The shares were sold at prices ranging from $101.28 to $107.00 per share. Oruka's stock currently trades at $105.35, not far from its 52-week high of $115.52. Over the past year, the shares have delivered a return of 289%. According to InvestingPro analysis, which provides Fair Value estimates and additional ProTips for ORKA, the stock appears overvalued at current levels.
On the same date, Agarwal acquired 10,000 shares of common stock through the exercise of employee stock options. These shares were obtained at prices between $12.50 and $34.39, for a total cost of approximately $156,915. The options carry various vesting schedules, with some vesting monthly beginning January 1, 2025, and others beginning January 1, 2026.
Following the reported transactions, Agarwal directly holds 14,219 shares of Oruka Therapeutics common stock and continues to hold 55,417 employee stock options.
In other recent developments, Oruka Therapeutics has drawn attention following the release of promising clinical trial data for its psoriasis treatment, ORKA-001. The company reported positive Week 16 results from its EVERLAST-B Phase 2b trial, which enrolled 187 patients and demonstrated significant improvements in moderate-to-severe plaque psoriasis. The 600mg dose achieved a 61% PASI-100 score, indicating complete skin clearance for a substantial portion of participants.
H.C. Wainwright and Guggenheim both reiterated their Buy ratings for Oruka Therapeutics, with price targets of $120 and $200, respectively. Piper Sandler also maintained an Overweight rating with a $180 price target, citing the strength of Oruka's drug pipeline as a key factor. Additionally, the EVERLAST-A Phase 2a trial results showed an increase in PASI 100 rates to 71.4% at Week 28, further underscoring the treatment's efficacy.
Despite these positive developments, Oruka's stock experienced a decline that was not linked to any negative trial outcomes. These updates reflect ongoing interest and confidence from analysts in Oruka Therapeutics' clinical advancements.